{"title": "Product Pipeline | CSL", "author": null, "url": "https://www.csl.com/research-and-development/product-pipeline", "hostname": "csl.com", "description": "CSL's product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.", "sitename": "CSL", "date": "2023-01-01", "cleaned_text": "Product Pipeline Focused on Innovation CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people's lives depend on it, CSL's R&D fuels the company's sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma protein technology, recombinant technology, cell and gene therapy and vaccines technology to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in six Therapeutic Areas - Immunology, Hematology, Respiratory, Cardiovascular and Metabolic, Transplant and Vaccines. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth. Core Capabilities as demonstrated in our product pipeline Phase I Phase II Phase III Registration / Post-Registration [](#) Anumigilimab (CSL324) the cytokine granulocyte colony stimulating factor receptor for the potential treatment of Hidradenitis Suppurativa (HS). [](#) Novel recombinant trivalent human IgG1 Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases such Myasthenia Gravis (MG) multimer for treatment of patients with immune complex-mediated autoimmune diseases such Myasthenia Gravis (MG) and Lupus of Vascular Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) patients. [](#) CSL787 Nebulised Ig Human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as IL-3 and IL-5 signalling by neutralising the \u00df-common receptor for the potential treatment of complex inflammatory diseases such as asthma. [](#) INS-3001 is a first-in-class drug based on inositol phosphate (IP6) (a natural substance found in all eukaryotic cells) in non-dialysis treatments for soft tissue and vascular calcification disorders. INS-3001 Calcification inhibitor (PAD, AVS) first-in-class drug based on inositol phosphate (IP6) (a natural substance found in all eukaryotic cells) in non-dialysis treatments for soft (SSc) mAb (sPE) being developed to dissolve thrombi that cause serious conditions such as submassive pulmonary embolism potential treatment of Interstitial (IL-6) for the potential treatment of end stage kidney disease (ESKD) in patients undergoing dialysis . [](#) Adjuvanted Cell Culture Influenza Vaccine (aQIVc) Adjuvanted Cell Culture Influenza Vaccine (aQIVc) combines FLUCELVAX\u00ae antigen with MF59\u00ae adjuvant (an additive that acts to strengthen the immune response to vaccination) to protect against four seasonal strains of influenza. [](#) Recombinant monoclonal antibody against the granulocyte macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases such as Giant Cell Arthritis (GCA & COVID-19). Mavrilimumab Anti-GM-CSFR macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases such as Giant Cell Arthritis (GCA & COVID-19). *Licensed to Kiniksa Pharmaceuticals. [](#) Monoclonal antibody targeting IL-13R1 for subcutaneous administration. [](#) HIZENTRA\u00ae (DM) 20% subcutaneous immunoglobulin for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM). [](#) KCENTRA\u00ae 4F-PCC (Trauma) A 4-factor prothrombin complex concentrate (4F-PCC) for the potential treatment of massive hemorrhage associated with severe traumatic injury. [](#) CSL112 apoA-I (AMI) Novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI). [](#) targeting (IL-6) for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients. [](#) CSL964 Alpha-1 Antitrypsin (Prevention of GvHD) Prevention of acute Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin Treatment of steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic (HSCT) steroid refractory, acute Graft-versus-Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic stem cell transplant (HSCT) using Alpha-1 Antitrypsin (AAT). *In collaboration with Blood and Marrow Transplant Clinical Trials Network (BMT CTN) [](#) mRNA vaccine is being developed for the prevention of COVID-19 infections. ARCT-154* COVID-19 Vaccine mRNA vaccine is being developed for the prevention of COVID-19 infections. * Transaction with Arcturus Therapeutics is subject to customary regulatory clearances before closing Ferric carboxymaltose (HF-ID) High dose intravenous iron (ferric carboxymaltose) for the treatment of iron deficiency in heart failure patients. [](#) Sparsentan Dual ETA & AT1 antagonist (FSGS) High antagonist of endothelin type A (ETA) & angiotensin type for treatment of focal antagonist of endothelin type A (ETA) & angiotensin type for Peripheral Artery Disease (PAD) in patients with end-stage Novel, recombinant factor VIII product for the treatment of adults and children with hemophilia A. [](#) IDELVION\u00ae rFIX-FP (Hem B) Novel, long-acting recombinant factor IX product for the treatment of hemophilia B. [](#) Etranacogene dezaparvovec (Hem B) Recombinant adeno-associated viral vector of serotype 5 (AAV5) gene therapy containing the Padua variant of a codon-optimized human FIX complementary deoxyribonucleic acid (AAV5-Padua hFIX) for CSL Seqirus' proprietary adjuvant, MF59\u00ae (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain. CSL Seqirus' proprietary adjuvant, MF59\u00ae (an additive that acts to strengthen the immune response to vaccination), to protect against influenza A (H5N1) - the 'bird-flu' strain. [](#) Seasonal egg-based, split virion quadrivalent influenza vaccine registered in the US and Australia for use in children 6 months of age and older. [](#) FLUAD\u00ae Trivalent Adjuvanted Influenza Vaccine Seasonal, egg-based with Seqirus' proprietary adjuvant, MF59\u00ae (an additive that acts to strengthen the immune response to vaccination) to protect against three different strains of influenza. [](#) FLUAD\u00ae Quadrivalent Adjuvanted Influenza Vaccine Seasonal, CSL Seqirus' proprietary adjuvant, MF59\u00ae (an additive that acts to strengthen the immune response to vaccination) to protect against four different strains of influenza. [](#) FLUCELVAX\u00ae Quadrivalent Cell-based Influenza Vaccine Seasonal cell culture-based, quadrivalent influenza vaccine offering protection against four different strains for use in children 6 months of age and older. [](#) PANVAX\u00ae Egg-based Influenza Vaccine Pre-pandemic, egg-based vaccine to protect (H1N1) - the 'swine-flu' strain. [](#) dose intravenous iron (ferric carboxymaltose) for the treatment of iron deficiency and iron deficient anaemia, where oral iron is ineffective or cannot be used or when there is a clinical need to deliver iron rapidly. [](#) KORSUVATM / of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult patients on haemodialysis. [](#) RAYALDEE\u00ae Oral ext. release calcifediol (SHPT) Orally administered, prolonged-release formulation of calcifediol for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency or deficiency. [](#) TAVNEOS\u00ae Oral C5a receptor inhibitor (AAV) Orally administered, highly potent and selective inhibitor of C5aR1 (complement C5a receptor 1) binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis or peritoneal dialysis. [](#) VELTASSA\u00ae Oral potassium binder (HK) A non-absorbed, oral potassium binder for the treatment of hyperkalemia. [](#) MIRCERA\u00ae long-acting erythropoiesis-stimulating agent (ESA) licensed from F. Hoffmann-La Roche AG in 2015 to treat symptomatic anaemia associated with chronic kidney disease. [](#) RETACRIT\u00ae short-acting ESA is a short-acting erythropoiesis-stimulating agent the first biosimilar ESA approved in the US. CSL has licensed rights from Pfizer Inc., in 2015 to commercialise Retacrit\u00ae in the US dialysis and non-hospital market for anaemia associated with chronic kidney disease. *Indicates partnered projects "}